A Randomized, Cross-over, Placebo-controlled, Double-blind, Single-center, Phase II Study of Cetuximab in Patients With Treatment-refractory, Non-malignant Severe Chronic Neuropathic Pain
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2016
At a glance
- Drugs Cetuximab (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Acronyms NoTOPain
- 07 Nov 2016 Status changed from active, no longer recruiting to completed.
- 18 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Oct 2016.
- 18 Oct 2016 Status changed from recruiting to active, no longer recruiting.